NCT02168920View on ClinicalTrials.gov

Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

PHASE3TerminatedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 11, 2014

Primary Completion Date

March 18, 2016

Study Completion Date

March 18, 2016

Conditions
Agitation Associated With Dementia of the Alzheimer's Type
Interventions
DRUG

2 mg/day

Once daily for 10 weeks

DRUG

3 mg/day

Once daily for 10 weeks

DRUG

6 mg/day

Once daily for 10 weeks

DRUG

Placebo (0 mg/day)

Once daily for 10 weeks

Trial Locations (1)

Unknown

Kanto Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT02168920 - Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type | Biotech Hunter | Biotech Hunter